Prot #BAY-1187982-16897: An Open-Label, Phase I, Dose-Escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-FGFR2 Antibody Drug Conjugate BAY 1187982 in Subjects with Advanced Sol

Project: Research project

Project Details

StatusFinished
Effective start/end date3/20/15 → 12/18/17

Funding

  • Covance Inc. (Prot #BAY-1187982-16897)
  • Bayer HealthCare Pharmaceuticals, Inc. (Prot #BAY-1187982-16897)